Milestone Pharmaceuticals (MIST) Income from Continuing Operations: 2020-2021
Historic Income from Continuing Operations for Milestone Pharmaceuticals (MIST) over the last 2 years, with Dec 2021 value amounting to -$42.9 million.
- Milestone Pharmaceuticals' Income from Continuing Operations fell 2.33% to -$14.6 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$58.2 million, marking a year-over-year change of. This contributed to the annual value of -$42.9 million for FY2021, which is 14.24% up from last year.
- Latest data reveals that Milestone Pharmaceuticals reported Income from Continuing Operations of -$42.9 million as of FY2021, which was up 14.24% from -$50.0 million recorded in FY2020.
- In the past 5 years, Milestone Pharmaceuticals' Income from Continuing Operations registered a high of -$42.9 million during FY2021, and its lowest value of -$50.0 million during FY2020.
- Moreover, its 2-year median value for Income from Continuing Operations was -$46.4 million (2020), whereas its average is -$46.4 million.
- Data for Milestone Pharmaceuticals' Income from Continuing Operations shows a peak YoY climbed of 14.24% (in 2021) over the last 5 years.
- Over the past 2 years, Milestone Pharmaceuticals' Income from Continuing Operations (Yearly) stood at -$50.0 million in 2020, then grew by 14.24% to -$42.9 million in 2021.